Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A survey assessing the impact of COVID-19 and elexacaftor/tezacaftor/ifavacaftor on both physical and mental health in adults with cystic fibrosis.

Pediatric pulmonology - 1 Mar 2023

Sakon Colleen, Vogt Hilary, Brown Cynthia D, Tillman Emma M

Abstract excerpt

In this letter to the editor, we report 82 persons with CF (PwCF) self-reported changes in mental and physical health and potential attribution with either the COVID-19 pandemic and the initiation elexacaftor/tezacaftor/ivacaftor (ETI). Emerging evidence has shown an association with ETI and mental health adverse events. The close proximity of ETI FDA approval and prescribing in PwCF and the COVID-19 pandemic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chloride Channel Agonists

Share to COVID-19

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Mental Health

Share to Pandemics

Share to Self Report

Source

Identifiers

PMID: 36482831
DOI: 10.1002/ppul.26260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A survey assessing the impact of COVID-19 and elexacaftor/tezacaftor/ifavacaftor on both physical and mental health in adults with cystic fibrosis.PMID 36482831Read ↗

Suicide attempts in adolescents with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor therapy.Semantic proximity Read ↗

DEPRESSION AND ANXIETY SYMPTOMS FOLLOWING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN ADULTS WITH CYSTIC FIBROSISSemantic proximity Read ↗

Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers.Semantic proximity Read ↗

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis.Semantic proximity Read ↗

Unveiling the Psychosocial Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Cystic Fibrosis PatientsSemantic proximity Read ↗

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational StudySemantic proximity Read ↗

Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.Semantic proximity Read ↗

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.Semantic proximity Read ↗

Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study.Semantic proximity Read ↗

Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.